Baxter International Inc. (BAX)
Baxter International Unveils IV Verify to Enhance IV Labeling Accuracy
BAX introduces the IV Verify system to improve IV labeling accuracy, targeting medication safety gaps and boosting workflow efficiency in clinical settings.
EU regulator warns of shortage in Baxter's cancer treatment until early 2027
The European Union's medicines regulator said on Tuesday it expects Baxter International's cancer drugs containing ifosfamide will remain in shortage in the bloc well into the first quarter of next year.
Baxter International Inc. (BAX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Baxter International Inc. (BAX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Sticking With Baxter At The Lows
Baxter International faces deep investor skepticism after disappointing guidance and management's decision to delay its Investor Day. Recent leadership changes and a flattened organizational structure are part of a turnaround effort, which is off to an admittedly bumpy start. But valuation is reasonable enough that BAX is a straight bet on the turnaround working.
Baxter International Inc. (BAX) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript
Baxter International Inc. (BAX) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript
Baxter International: Debt, Margin Pressure, Dreadful FY26 Guidance (Downgrade)
Baxter International faces a fundamental downturn after weak Q4 results and a dismal FY 2026 guide, prompting a hold rating downgrade. BAX trades at a very cheap valuation, but persistent margin compression, debt risks, and repeated earnings disappointments overshadow near-term recovery prospects. Despite some growth in Advanced Surgery and new connected care offerings, operational efficiency and profitability remain under severe pressure.
BAX Stock Falls Following Q4 Earnings Miss, Margins Contract
Baxter International misses Q4 EPS estimates as margins shrink, even as revenues top forecasts; shares slide 12.5% on weak 2026 guidance.
Baxter (BAX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Baxter (BAX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Baxter International (BAX) Q4 Earnings Lag Estimates
Baxter International (BAX) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.58 per share a year ago.
Baxter to Post Q4 Earnings: What's in Store for the Stock?
BAX's fourth-quarter results are likely to reflect muted revenue growth and an EPS decline due to ongoing infusion therapy and IV fluid headwinds.
Reasons to Retain Baxter International Stock in Your Portfolio Now
BAX is reshaping its portfolio following the divestiture of its Kidney Care business, focusing on surgical strength, deleveraging and tighter execution to rebuild momentum.
The Bottom Fishing Club - Baxter: Defensive Pick, Restructuring And Paying Down Debt
Baxter International offers a compelling defensive play, trading at historically low valuations after significant deleveraging and operational headwinds. BAX's forward cash earnings multiple is around 8x, notably cheaper than hospital and consumer health product peers, despite slightly weaker gross profit margins. Management's focus on debt reduction and cost controls positions BAX for margin expansion and potential sales growth into 2027.
